☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
BeiGene
BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia
January 20, 2023
BeiGene Reports the NMPA’s Acceptance of sBLA for Tislelizumab for 1L Treatment of Hepatocellular Carcinoma
January 2, 2023
Insights+: EMA Marketing Authorization of New Drugs in November 2022
December 28, 2022
PharmaShots Weekly Snapshots (December 05–09, 2022)
December 9, 2022
BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment Chronic Lymphocytic Leukemia
November 18, 2022
BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment of Adults with Marginal Zone Lymphoma
November 2, 2022
Load more...
Back to Home